{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T18:50:23Z","timestamp":1732042223534},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,5]]},"DOI":"10.7759\/cureus.32240","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T07:44:32Z","timestamp":1670312672000},"source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis (RA): A Retrospective Study From Two Centers in Jeddah, Saudi Arabia"],"prefix":"10.7759","author":[{"given":"Zeyad","family":"Alzahrani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Alhazmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanan","family":"Almalki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noura","family":"Aljehani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Dumyati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadeel","family":"Alabdali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10513","article-title":"Long-term outcome in rheumatoid arthritis: a simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup","volume":"47","author":"Drossaers-Bakker KW","year":"2002","unstructured":"Drossaers-Bakker KW, Zwinderman AH, Vliet Vlieland TP, Van Zeben D, Vos K, Breedveld FC, Hazes JM. Long-term outcome in rheumatoid arthritis: a simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup. Arthritis Rheum. 2002, 47:383-390. 10.1002\/art.10513","journal-title":"Arthritis Rheum"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen JS","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RB, Bijlsma JW, et al.. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020, 79:685-699. 10.1136\/annrheumdis-2019-216655","journal-title":"Ann Rheum Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177057","article-title":"Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis","volume":"12","author":"Iwamoto N","year":"2017","unstructured":"Iwamoto N, Tsuji S, Takatani A, et al.. Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis. PLoS One. 2017, 12:e0177057. 10.1371\/journal.pone.0177057","journal-title":"PLoS One"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.191252","article-title":"Tofacitinib persistence in patients with rheumatoid arthritis: a retrospective cohort study","volume":"48","author":"Fisher A","year":"2021","unstructured":"Fisher A, Hudson M, Platt RW, Dormuth CR. Tofacitinib persistence in patients with rheumatoid arthritis: a retrospective cohort study. J Rheumatol. 2021, 48:16-24. 10.3899\/jrheum.191252","journal-title":"J Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20494","article-title":"Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"63","author":"Tanaka Y","year":"2011","unstructured":"Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken). 2011, 63:1150-1158. 10.1002\/acr.20494","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven RF","year":"2012","unstructured":"van Vollenhoven RF, Fleischmann R, Cohen S, et al.. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012, 367:508-519. 10.1056\/NEJMoa1112072","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"crossref","DOI":"10.2146\/news120088","article-title":"FDA approves tofacitinib for rheumatoid arthritis","volume":"69","author":"Traynor K","year":"2012","unstructured":"Traynor K. FDA approves tofacitinib for rheumatoid arthritis. Am J Health Syst Pharm. 2012, 69:2120-2121.","journal-title":"Am J Health Syst Pharm"},{"key":"ref8","article-title":"EMA confirms Xeljanz to be used with caution in patients at high risk of blood clots","author":"Xeljanz","year":"2019","unstructured":"Xeljanz. EMA confirms Xeljanz to be used with caution in patients at high risk of blood clots. European Medicines Agency. 2019,","journal-title":"European Medicines Agency"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11232","article-title":"Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States-based rheumatoid arthritis registry","volume":"3","author":"Kremer JM","year":"2021","unstructured":"Kremer JM, Bingham CO 3rd, Cappelli LC, et al.. Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States-based rheumatoid arthritis registry. ACR Open Rheumatol. 2021, 3:173-184. 10.1002\/acr2.11232","journal-title":"ACR Open Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg SR","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al.. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022, 386:316-326. 10.1056\/NEJMoa2109927","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha D","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, et al.. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010, 62:2569-2581. 10.1002\/art.27584","journal-title":"Arthritis Rheum"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21649","article-title":"Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice","volume":"64","author":"Anderson J","year":"2012","unstructured":"Anderson J, Caplan L, Yazdany J, et al.. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken). 2012, 64:640-647. 10.1002\/acr.21649","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref13","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): A phase 3b\/4, double-blind, head-to-head, randomized controlled trial","volume":"390","author":"Fleischmann R","year":"2017","unstructured":"Fleischmann R, Mysler E, Hall S, et al.. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): A phase 3b\/4, double-blind, head-to-head, randomized controlled trial. Lancet. 2017, 390:457-468.","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee EB","year":"2014","unstructured":"Lee EB, Fleischmann R, Hall S, et al.. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014, 370:2377-2386. 10.1056\/NEJMoa1310476","journal-title":"N Engl J Med"},{"key":"ref15","article-title":"Effectiveness, tolerability, and safety of tofacitinib in rheumatoid arthritis: a retrospective analysis of real-world data from the St. Gallen and Aarau cohorts","volume":"8","author":"Mueller RB","year":"2019","unstructured":"Mueller RB, Hasler C, Popp F, et al.. Effectiveness, tolerability, and safety of tofacitinib in rheumatoid arthritis: a retrospective analysis of real-world data from the St. Gallen and Aarau cohorts. J Clin Med\u200f. 2019, 8:1548.","journal-title":"J Clin Med\u200f"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2147\/OARRR.S322086","article-title":"Tofacitinib: real-world data and treatment persistence in rheumatoid arthritis","volume":"13","author":"Bertoldi I","year":"2021","unstructured":"Bertoldi I, Caporali R. Tofacitinib: real-world data and treatment persistence in rheumatoid arthritis. Open Access Rheumatol. 2021, 13:221-237. 10.2147\/OARRR.S322086","journal-title":"Open Access Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-207178","article-title":"Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs","volume":"75","author":"Charles-Schoeman C","year":"2016","unstructured":"Charles-Schoeman C, Burmester G, Nash P, et al.. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2016, 75:1293-1301. 10.1136\/annrheumdis-2014-207178","journal-title":"Ann Rheum Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1866-2","article-title":"Safety and efficacy of tofacitinib for up to 9.5\u2009years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study","volume":"21","author":"Wollenhaupt J","year":"2019","unstructured":"Wollenhaupt J, Lee EB, Curtis JR, et al.. Safety and efficacy of tofacitinib for up to 9.5\u2009years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019, 21:89. 10.1186\/s13075-019-1866-2","journal-title":"Arthritis Res Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-011-0516-6","article-title":"Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study)","volume":"22","author":"Takeuchi T","year":"2012","unstructured":"Takeuchi T, Tanaka Y, Kaneko Y, et al.. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Modern Rheumatol. 2012, 22:327-338. 10.3109\/s10165-011-0516-6","journal-title":"Modern Rheumatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.9341-17","article-title":"Tofacitinib therapy for rheumatoid arthritis: a direct comparison study between biologic-na\u00efve and experienced patients","volume":"57","author":"Mori S","year":"2017","unstructured":"Mori S, Yoshitama T, Ueki Y. Tofacitinib therapy for rheumatoid arthritis: a direct comparison study between biologic-na\u00efve and experienced patients. Intern Med. 2017, 57:663-670. 10.2169\/internalmedicine.9341-17","journal-title":"Intern Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3906\/sag-2007-123","article-title":"Efficacy, retention, and safety of tofacitinib in real-life: Hur-bio monocentric experience","volume":"51","author":"Bilgin E","year":"2021","unstructured":"Bilgin E, Ceylan F, Duran E, et al.. Efficacy, retention, and safety of tofacitinib in real-life: Hur-bio monocentric experience. Turk J Med Sci. 2021, 51:297-308. 10.3906\/sag-2007-123","journal-title":"Turk J Med Sci"},{"key":"ref22","article-title":"Infection events in Japanese patients with rheumatoid arthritis treated with tofacitinib: interim all-case post-marketing surveillance (2018) ACR Meeting Abstracts","author":"Tamura N","year":"2018","unstructured":"Tamura N, Kuwana M, Atsumi T, et al.. Infection events in Japanese patients with rheumatoid arthritis treated with tofacitinib: interim all-case post-marketing surveillance (2018) ACR Meeting Abstracts. Arthritis Rheumatol. Wiley, NJ, USA; 2018. 70:"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.03.004","article-title":"Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist","volume":"46","author":"Charles-Schoeman C","year":"2016","unstructured":"Charles-Schoeman C, Gonzalez-Gay MA, Kaplan I, et al.. Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist. Semin Arthritis Rheum. 2016, 46:71-80. 10.1016\/j.semarthrit.2016.03.004","journal-title":"Semin Arthritis Rheum"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/123580-efficacy-and-safety-of-tofacitinib-in-rheumatoid-arthritis-ra-a-retrospective-study-from-two-centers-in-jeddah-saudi-arabia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:43:52Z","timestamp":1707507832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/123580-efficacy-and-safety-of-tofacitinib-in-rheumatoid-arthritis-ra-a-retrospective-study-from-two-centers-in-jeddah-saudi-arabia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,5]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.32240","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,5]]}}}